drugset / Trial / NCT00325481

Study To Evaluate the Safety of Bivalent Vaccine

NCT00325481

Phase 3 Completed 300 enrolled MedImmune LLC
RandomizedSingle-groupDouble-blindTreatment

Summary

To assess the safety of a bivalent vaccine of two new influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them.

Timeline

Start
2006-06
Primary completion
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject FluMist Vaccine Intranasal

Indications

No indication recorded.